Journal article
Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative
KA Ellis, CC Rowe, VL Villemagne, RN Martins, CL Masters, O Salvado, C Szoeke, D Ames
Alzheimer S and Dementia | Published : 2010
Abstract
The Australian Imaging Biomarkers and Lifestyle (AIBL) study is a longitudinal study of 1112 volunteers from healthy, mild cognitive impairment, and Alzheimer's disease (AD) populations who can be assessed and followed up for prospective research into aging and AD. AIBL aims to improve understanding of the pathogenesis, early clinical manifestation, and diagnosis of AD, and identify diet and lifestyle factors that influence the development of AD. For AIBL, the magnetic resonance imaging parameters of Alzheimer's Disease Neuroimaging Initiative (ADNI) were adopted and the Pittsuburgh compound B ( 11 C-PiB) positron emission tomography (PET) acquisition and neuropsychological tests were design..
View full abstractGrants
Funding Acknowledgements
Core funding for the study was provided by Commonwealth Science and Industrial Research Organization. which was matched by contributions from the study partners. The study also received support from the National Health and Medical Research Council and the Dementia Collaborative Research Centres program (DCRC2) Pfizer International has contributed financial support to assist with analysis of blood samples and to further the AIBL research program. The Alzheimer's Association has contributed support to allow AIBL neuroimaging stream data (and accompanying clinical and cognitive data) to be made available through the ADNI website The authors thank Alzheimer's Australia (Victoria and Western Australia) who assisted with promotion of the study and screening, of telephone calls from volunteers, and collaborate with AIBL volunteer functions. Cassandra Szoeke is partially supported by the NHMRC and a research fellowship funded by Alzheimer's Australia The AIBL team wishes to thank all those who took part as subjects in the study for their commitment and dedication to helping advance research into the early detection and causation of AD